CompletedNCT00340379
Ziprasidone or combined antidepressant and antipsychotic treatment for psychotic depression
About this title
Read the official source — NCT00340379Medication studyAges 18–75Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- Los Angeles and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateApril 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, Egypt, India
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00340379
- Official title
Show the full official title
A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles, United States · Alexandria, Egypt · Bangalore, India
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone, Sertraline and Haloperidol.
Who was this study for?
Listed age limits: 18 years to 75 years.
